SCHEMBL29956653

SCHEMBL29956653

OB(O)c1cc(O)cc2ncccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
ALDH1A1 P00352 3/20 0.47
CASP1 P29466 2/20 0.47
CASP7 P55210 1/20 0.47
KDM4E B2RXH2 6/20 0.43
MAPT P10636 3/20 0.43
NR4A2 P43354 1/20 0.40
SYK P43405 2/20 0.38
HSP90AA1 P07900 5/20 0.38
NPC1 O15118 1/20 0.38
IDO1 P14902 1/20 0.38
RAB9A P51151 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ERN1 O75460 1/20 0.38
HTT P42858 4/20 0.37
SLC6A2 P23975 3/20 0.37
ALOX15 P16050 3/20 0.36
MAPK1 P28482 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542662 0.79 ALDH1A1 (0.48) MEN1KMT2AALDH1A1CASP1CASP7
SCHEMBL23884462 0.79 MEN1 (0.52) MEN1KMT2AALDH1A1CASP1CASP7
SCHEMBL29951591 0.78 TLR8 (0.49) MEN1KMT2AALDH1A1CASP1CASP7
SCHEMBL29956251 0.77 MAPT (0.52) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL20346 0.77 MAPT (0.52) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL30344938 0.76 KDM4E (0.53) MEN1KMT2AALDH1A1CASP1CASP7
SCHEMBL29955571 0.76 MAPT (0.56) MEN1KMT2ACASP1KDM4EMAPT
SCHEMBL18572649 0.76 KDM4E (0.53) MEN1KMT2AALDH1A1CASP1CASP7
SCHEMBL22719670 0.76 KDM4E (0.53) MEN1KMT2AALDH1A1CASP1CASP7
SCHEMBL29954354 0.75 ERN1 (0.54) MEN1KMT2AALDH1A1CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059205-A1 Heterocyclic Compounds and Methods of Use AMGEN INC. (US) 2025-02-20 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059205-A1 Heterocyclic Compounds and Methods of Use KRAS, NRAS, HRAS MEN1 310/4885KMT2A 2621/4885ALDH1A1 1275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.